
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10921715/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target. Amino Acids, 2017, 49, 425-439.	1.2	41
2	Transglutaminase-2. , 2017, , 4634-4637.		0
3	Transglutaminase II and Metastasis: How Hot Is the Link?. , 2015, , 215-228.		0
4	TG2: Player That Dictates the Rules in Cancer Progression. , 2015, , 129-136.		0
5	Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor. European Journal of Cancer, 2014, 50, 1685-1696.	1.3	24
6	Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. International Journal of Cancer, 2014, 134, 2798-2807.	2.3	45
7	Transglutaminase Regulation of Cell Function. Physiological Reviews, 2014, 94, 383-417.	13.1	353
8	Transglutaminase-2. , 2014, , 1-3.		1
9	Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?. Amino Acids, 2013, 44, 81-88.	1.2	39
10	Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Research, 2013, 15, 202.	2.2	78
11	Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway. PLoS ONE, 2012, 7, e49321.	1.1	84
12	Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Research, 2012, 14, R4.	2.2	54
13	Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. Cancers, 2011, 3, 897-912.	1.7	18
14	Evidence That Aberrant Expression of Tissue Transglutaminase Promotes Stem Cell Characteristics in Mammary Epithelial Cells. PLoS ONE, 2011, 6, e20701.	1.1	56
15	Transglutaminase-2. , 2011, , 3764-3766.		0
16	Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer. Biochemical Pharmacology, 2010, 80, 1921-1929.	2.0	129
17	Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells. PLoS ONE, 2010, 5, e13390.	1.1	110
18	Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model. Molecular Cancer Therapeutics, 2010, 9, 1180-1187.	1.9	37

#	Article	IF	CITATIONS
19	Tissue transglutaminase expression and drug resistance in ovarian cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 105-110.	0.4	0
20	Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells. , 2009, , 95-114.		6
21	Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Research, 2009, 29, 1909-19.	0.5	63
22	Liposome-Encapsulated Curcumin Suppresses Growth of Head and Neck Squamous Cell Carcinoma <i>In vitro</i> and in Xenografts through the Inhibition of Nuclear Factor κB by an AKT-Independent Pathway. Clinical Cancer Research, 2008, 14, 6228-6236.	3.2	193
23	Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Research, 2008, 68, 5849-5858.	0.4	90
24	Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 2476-2483.	3.2	95
25	Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells. Clinical Cancer Research, 2008, 14, 1997-2005.	3.2	84
26	PKCδ and Tissue Transglutaminase are Novel Inhibitors of Autophagy in Pancreatic Cancer Cells. Autophagy, 2007, 3, 480-483.	4.3	76
27	Tissue Transglutaminase Inhibits Autophagy in Pancreatic Cancer Cells. Molecular Cancer Research, 2007, 5, 241-249.	1.5	123
28	Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity. Current Cancer Drug Targets, 2007, 7, 559-565.	0.8	35
29	Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resistance Updates, 2007, 10, 144-151.	6.5	88
30	Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Molecular Cancer Therapeutics, 2007, 6, 1276-1282.	1.9	302
31	Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon-γ/interleukin-1β-dependent apoptosis of endothelial cells: Implications in the etiology of retinoic acid syndrome. Leukemia Research, 2007, 31, 455-463.	0.4	30
32	N-linked glycosylation of CD38 is required for its structure stabilization but not for membrane localization. Molecular and Cellular Biochemistry, 2007, 295, 1-7.	1.4	14
33	Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1455-1463.	2.2	29
34	Tissue transglutaminase: from biological glue to cell survival cues. Frontiers in Bioscience - Landmark, 2006, 11, 173.	3.0	70
35	Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-l°B in Cancer Cells: Delineation of a Novel Pathway. Cancer Research, 2006, 66, 8788-8795.	0.4	188
36	Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis. Cancer Research, 2006, 66, 10525-10533.	0.4	150

#	Article	IF	CITATIONS
37	Implications of tissue transglutaminase expression in malignant melanoma. Molecular Cancer Therapeutics, 2006, 5, 1493-1503.	1.9	97
38	Tissue Transglutaminase (TG2) in Cancer Biology. , 2005, 38, 125-138.		50
39	Mammalian Transglutaminases: A Family Portrait. , 2005, 38, 1-18.		44
40	Transglutaminases of Lower Organisms. , 2005, 38, 209-222.		1
41	Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Molecular Cancer, 2005, 4, 33.	7.9	139
42	Antitumor Metallothiosemicarbazonates:Â Structure and Antitumor Activity of Palladium Complex of Phenanthrenequinone Thiosemicarbazone. Inorganic Chemistry, 2005, 44, 1154-1156.	1.9	129
43	Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 8068-8076.	3.2	187
44	Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. Journal of Cellular Physiology, 2004, 200, 223-234.	2.0	50
45	Multidrug-Resistant MCF-7 Cells: An Identity Crisis?. Journal of the National Cancer Institute, 2002, 94, 1652-b-1654.	3.0	33
46	Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. International Journal of Oncology, 2002, 20, 913.	1.4	18
47	Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene, 2002, 21, 8843-8851.	2.6	383
48	Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Research and Treatment, 2002, 71, 237-247.	1.1	51
49	Retinoid-Mediated Signaling and CD38 Expression. , 2002, , 409-425.		3
50	Retinoic acida player that rules the game of life and death in neutrophils. Indian Journal of Experimental Biology, 2002, 40, 874-81.	0.5	2
51	Human CD38: a (r)evolutionary story of enzymes and receptors. Leukemia Research, 2001, 25, 1-12.	0.4	258
52	Retinoid-Mediated Signaling Pathways in CD38 Antigen Expression in Myeloid Leukemia Cells. Leukemia and Lymphoma, 1999, 32, 441-449.	0.6	18
53	Tissue transglutaminase: an enzyme with a split personality. International Journal of Biochemistry and Cell Biology, 1999, 31, 817-836.	1.2	171
54	Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anti-Cancer Drugs, 1997, 8, 470-481.	0.7	290

#	Article	IF	CITATIONS
55	Involvement of Retinoic Acid Receptor-α–Mediated Signaling Pathway in Induction of CD38 Cell-Surface Antigen. Blood, 1997, 89, 3607-3614.	0.6	53
56	Involvement of Retinoic Acid Receptor-α–Mediated Signaling Pathway in Induction of CD38 Cell-Surface Antigen. Blood, 1997, 89, 3607-3614.	0.6	3
57	Human CD38, a cellâ€surface protein with multiple functions. FASEB Journal, 1996, 10, 1408-1417.	0.2	264
58	Post-translational Modification of CD38 Protein into a High Molecular Weight Form Alters Its Catalytic Properties. Journal of Biological Chemistry, 1996, 271, 15922-15927.	1.6	60
59	High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. International Journal of Cancer, 1994, 58, 400-406.	2.3	106
60	Human CD38: a glycoprotein in search of a function. Trends in Immunology, 1994, 15, 95-97.	7.5	331
61	Purification and characterization of a novel transglutaminase from filarial nematode Brugia malayi. FEBS Journal, 1994, 225, 625-634.	0.2	39
62	Significance of transglutaminase-catalyzed reactions in growth and development of filarial parasite, Brugia malayi. Biochemical and Biophysical Research Communications, 1990, 173, 1051-1057.	1.0	21
63	Transglutaminase Levels and Immunologic Functions of BCG-Elicited Mouse Peritoneal Macrophages Isolated by Centrifugal Elutriation. Journal of Leukocyte Biology, 1989, 45, 434-443.	1.5	8
64	Induction of Adenosine Deaminase and 5′ Nucleotidase Activity in Cultured Human Blood Monocytes and Monocytic Leukemia (THP-1) Cells by Differentiating Agents. Journal of Leukocyte Biology, 1988, 44, 205-211.	1.5	16
65	Induction of Tissue Transglutaminase in Human Peripheral Blood Monocytes by Intracellular Delivery of Retinoids. Journal of Leukocyte Biology, 1987, 41, 341-348.	1.5	19